glycerol 1,3-didecanoate 2-eicosatetra-(5-Z, 8-Z, 11-Z, 14-Z)enoate

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 甘油脂
• 英文名称: glycerol 1,3-didecanoate 2-eicosatetra-(5-Z, 8-Z, 11-Z, 14-Z)enoate
• 英文别名: glycerol 1,3-didecanoate 2-eicosatetra-(5Z,8Z,11Z,14Z)enoate；1,3-di(decanoyloxy)propan-2-yl (5Z,8Z,11Z,14Z)-icosa-5,8,11,14-tetraenoate
• 化学式: C₄₃H₇₄O₆
• 分子量: 687.057
• InChiKey: YKNNEDHCJXFOAT-CANSCOPASA-N

计算性质

• 辛醇/水分配系数(LogP)：
  14.6
• 重原子数：
  49
• 可旋转键数：
  38
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.74
• 拓扑面积：
  78.9
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  二癸酸甘油酯 、 花生四烯酰氯 在 4-二甲氨基吡啶 吡啶 作用下， 以 二氯甲烷 为溶剂， 以56%的产率得到glycerol 1,3-didecanoate 2-eicosatetra-(5-Z, 8-Z, 11-Z, 14-Z)enoate
  参考文献：
  名称：

  [EN] TREATMENT OF NEURODEGENERATIVE CONDITIONS
  [FR] TRAITEMENT D'ETATS NEURODEGENERATIFS

  摘要：

  提供了一种治疗神经退行性疾病患者的方法，包括向该患者施用含有甘油基团和脂肪酸基团的治疗有效剂量的脂质甘油酯，所述脂肪酸基团选自Ϝ-亚麻酸、二油酸和花生四烯酸组成的群体，其特点在于所选的脂肪酸基团附着在甘油基团的sn-2位置。最好的方法是，脂质被施用的持续时间和剂量足以维持或提高患者体内TGF-β1水平至治疗水平。

  公开号：

  WO2005018632A1

文献信息

• TREATMENT OF NEURODEGENERATIVE CONDITIONS
  申请人：BTG INTERNATIONAL LIMITED

  公开号：EP1660071A1

  公开（公告）日：2006-05-31
• Treatment of Neurodegenerative Conditions
  申请人：Harbige Laurence S.

  公开号：US20080194684A1

  公开（公告）日：2008-08-14

  A method is provided for treating a patient in need of therapy for a neurodegenerative disease comprising administering to that patient a therapeutically effective dose of a lipid glyceride comprising a glycerol moiety and a fatty acid moiety, the fatty acid moiety being selected from the group consisting of γ-linolenic acid, dihomo-γ-linolenic acid and arachidonic acid characterised in that the selected fatty acid moiety is attached to the glycerol moiety at its sn-2 position. Preferably the method is that wherein the lipid is administered for a duration and at a dose sufficient to maintain or elevate TGF-β levels in the patient to therapeutic levels.
• Treatment of neurodegenerative conditions
  申请人：Harbige Lawrence S.

  公开号：US20100113595A1

  公开（公告）日：2010-05-06

  A method is provided for treating a patient in need of therapy for a neurodegenerative disease comprising administering to that patient a therapeutically effective dose of a lipid glyceride comprising a glycerol moiety and a fatty acid moiety, the fatty acid moiety being selected from the group consisting of γ-linolenic acid, dihomo-γ-linolenic acid and arachidonic acid characterised in that the selected fatty acid moiety is attached to the glycerol moiety at its sn-2 position. Preferably the method is that wherein the lipid is administered for a duration and at a dose sufficient to maintain or elevate TGF-β1 levels in the patient to therapeutic levels.